Evolus has expanded its strategic partnership with Symatese to commercialize Estyme—a botulinum toxin A product—across Canada, Australia, and New Zealand. Estyme is positioned as a rapid-onset, long-duration neuromodulator, competing directly with Jeuveau (Evolus's own toxin) and Botox in these markets.
Business & M&A
Evolus Expands Estyme to Canada, Australia, New Zealand
Strategic partnership with Symatese accelerates international rollout of Jeuveau competitor.
1-YEAR MOVE
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
Evolus is betting on Estyme to compete across three major markets.
The move signals Evolus's confidence in Estyme's clinical profile and market differentiation, while leveraging Symatese's regional distribution and regulatory expertise. For North American practices, this represents incremental competitive pressure in the toxin category, particularly as Estyme gains regulatory approvals and market share in adjacent geographies. The partnership also indicates Evolus is diversifying its toxin portfolio beyond Jeuveau, hedging against biosimilar erosion and expanding addressable market.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.